Loading…
Lineage Cell Therapeutics, Inc. is projected to rise to $1.47 by 2027, a +15% move from its current price of $1.28. LCTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $1.25 | $1.28 | $1.31 | -0.03% |
| Jul 15 | $1.24 | $1.28 | $1.32 | -0.05% |
| Jul 16 | $1.23 | $1.28 | $1.33 | -0.08% |
| Jul 17 | $1.22 | $1.28 | $1.34 | -0.10% |
| Jul 18 | $1.21 | $1.28 | $1.35 | -0.13% |
| Jul 19 | $1.20 | $1.28 | $1.36 | -0.15% |
| Jul 20 | $1.20 | $1.28 | $1.36 | -0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.20 | $1.28 | $1.36 | -0.18% |
| Week 2 | $1.16 | $1.28 | $1.40 | -0.35% |
| Week 3 | $1.14 | $1.27 | $1.42 | -0.53% |
| Week 4 | $1.12 | $1.27 | $1.45 | -0.70% |
| Week 5 | $1.10 | $1.27 | $1.47 | -0.88% |
| Week 6 | $1.08 | $1.27 | $1.48 | -1.05% |
| Week 7 | $1.07 | $1.26 | $1.50 | -1.23% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic and oncologic disorders.
The company has collaboration agreements with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates.
The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Lineage Cell Therapeutics, Inc. (LCTX) is a healthcare stock currently trading at $1.35 with a market capitalization of $336.55M and a rank of 3225. The price outlook is buoyant over the longer horizon, with a path of gradual increases across the listed forecast years and bullish sentiment from 2027 onward.
In 2026, the average forecast is $1.35 with a neutral sentiment and a 0% ROI. By 2030, the average rises to $2.50 with an 85.1% ROI and a bullish outlook. The forecast continues to imply upside through 2040 (average $4.95, ROI 266.8%, bullish) and into 2050 (average $9.49, ROI 602.9%, bullish), with the maximum predicted prices climbing to $3.63 in 2030, $8.33 in 2040, and $17.45 in 2050.
A major floor 13.0% below — a decisive break under it would weaken the trend.
The nearest floor, 7.0% below — buyers have tended to step in here.
The nearest ceiling, 5.5% above — a clean break opens room to run.
A major ceiling 52.3% above — clearing it would confirm fresh momentum.
Key LCTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LCTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.31 | Sell | $1.30 | Sell |
| MA 10 | $1.31 | Sell | $1.30 | Sell |
| MA 20 | $1.28 | Buy | $1.29 | Sell |
| MA 50 | $1.30 | Sell | $1.33 | Sell |
| MA 100 | $1.47 | Sell | $1.41 | Sell |
| MA 200 | $1.59 | Sell | $1.42 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.31 | Neutral |
| Stoch RSI (14) | 33.35 | Neutral |
| CCI (20) | 1.85 | Neutral |
| Williams %R (14) | -53.85 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 2.40 | Buy |
| Bollinger %B (20,2) | 0.51 | Neutral |
| Stochastic %K (14) | 46.15 | Neutral |
| TRIX (15) | 0.00 | Buy |
| Awesome (5,34) | 0.04 | Buy |
| Ultimate (7,14,28) | 46.77 | Neutral |
| Momentum (10) | 0.06 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 1.30 | Sell |
| ADX (14) | 11.65 | Neutral |
| ATR (14) | 0.03 | Info |
The near-term technical picture remains bullish with the stock trading around the 50-day simple moving average. RSI14 is 60, indicating room to move higher without overbought risk. The 30-day range spans $1.13 to $1.61, while the price currently sits at $1.35.
The SMA50 is $1.35 and the SMA200 is $1.60, with support at $1.19 and resistance at $1.35. Annualized volatility sits at 50%, suggesting notable but manageable short-term variation.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.19 | $1.28 | $1.58 | 0% | Neutral | |
| $1.18 | $1.47 | $1.93 | +15% | Neutral | |
| $1.33 | $1.69 | $2.29 | +32% | Bullish | |
| $1.44 | $1.88 | $2.61 | +47% | Bullish | |
| $1.60 | $2.12 | $3.02 | +66% | Bullish | |
| $1.53 | $2.06 | $2.98 | +61% | Bullish | |
| $1.52 | $2.08 | $3.07 | +62% | Bullish | |
| $1.69 | $2.35 | $3.52 | +83% | Bullish | |
| $1.88 | $2.64 | $4.01 | +106% | Bullish | |
| $2.13 | $3.03 | $4.67 | +137% | Bullish | |
| $2.54 | $3.82 | $6.23 | +198% | Bullish | |
| $4.28 | $7.12 | $12.62 | +456% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.19 | $1.28 | $1.51 | +0.00% |
| August 2026 | $1.05 | $1.23 | $1.49 | -3.69% |
| September 2026 | $1.06 | $1.25 | $1.52 | +1.47% |
| October 2026 | $1.08 | $1.29 | $1.59 | +3.20% |
| November 2026 | $1.07 | $1.28 | $1.58 | -0.92% |
| December 2026 | $1.05 | $1.27 | $1.58 | -1.08% |
Click any year to see its month-by-month LCTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect LCTX to range from $1.19 to $1.58 through 2026. The $1.28 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The LCTX price prediction for 2027 points to an average of $1.47 (low $1.18, high $1.93) — a potential gain of +15% on today's $1.28. A consolidation phase looks the most probable path here.
In 2028, LCTX is projected to trade between $1.33 and $2.29, averaging $1.69 — a potential gain of +32% from today's $1.28. That is up +15% on the projected 2027 average. Momentum favours further upside here.
Lineage Cell Therapeutics, Inc.'s 2029 outlook centres on $1.88, within a $1.44 to $2.61 range. That is up +11% on the projected 2028 average. That marks a +47% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, LCTX could reach as high as $3.02, with a base case around $2.12 and support toward $1.60 — roughly +66% from $1.28. Momentum favours further upside here.
Expect LCTX to range from $1.53 to $2.98 through 2031. The $2.06 average target implies a +61% move from current prices. That is -3% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
The LCTX price prediction for 2032 points to an average of $2.08 (low $1.52, high $3.07) — a potential gain of +62% on today's $1.28. Momentum favours further upside here.
In 2033, LCTX is projected to trade between $1.69 and $3.52, averaging $2.35 — a potential gain of +83% from today's $1.28. That is up +13% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Lineage Cell Therapeutics, Inc.'s 2034 outlook centres on $2.64, within a $1.88 to $4.01 range. That is up +12% on the projected 2033 average. That marks a +106% change versus current levels. Momentum favours further upside here.
By 2035, LCTX could reach as high as $4.67, with a base case around $3.03 and support toward $2.13 — roughly +137% from $1.28. Buyers look set to stay in control over this stretch.
Expect LCTX to range from $2.54 to $6.23 through 2040. The $3.82 average target implies a +198% move from current prices. That is up +26% on the projected 2035 average. Momentum favours further upside here.
The LCTX price prediction for 2050 points to an average of $7.12 (low $4.28, high $12.62) — a potential gain of +456% on today's $1.28. Buyers look set to stay in control over this stretch.
Investing $1,000 in LCTX today (≈ 781.25 LCTX) could be worth
$5,561.37
+$4,561.37 (+456%) by 2050 · US Dollar
Based on the average projected LCTX price of $7.12 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LCTXwould be worth at today's price.
$1,000 invested in LCTX on Jul 10, 2025 (≈ 980.392175 LCTX) would be worth
$1,254.9
+$254.9 (+25.5%) today · 1.25× · US Dollar
Based on a LCTX entry price of $1.02 vs. today's $1.28.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.35 | $948.15 | -5.2% |
| 1 month ago | $1.23 | $1,040.65 | +4.1% |
| 3 months ago | $1.48 | $864.86 | -13.5% |
| 6 months ago | $1.76 | $727.27 | -27.3% |
| 1 year ago | $1.02 | $1,254.9 | +25.5% |
| All time (5.0y) ago | $2.73 | $468.86 | -53.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LCTX forecast.
Our base-case forecast reaches $2.60 around 2034.
Implied market cap at $2.60: $648.18M
The multi-year forecast shows a clear upward trajectory in the average price from 2026 through 2050, with bullish sentiment intensifying after 2026. The 2030 forecast lists an average of $2.50 (min $1.86, max $3.63) with an 85.1% ROI, and a bullish outlook. By 2040, the average is expected to reach $4.95 (min $3.18, max $8.33) with a 266.8% ROI, still bullish.
The 2050 forecast projects an average of $9.49 (min $5.44, max $17.45) with a 602.9% ROI, continuing a bullish trend.
These are estimates and not guarantees. The results reflect a high upside potential over the long horizon but also carry inherent uncertainty and risk. The trajectory suggests meaningful upside beyond 2026, but investors should consider the inherent variability in forecasted crypto-equivalent equity figures and the specific risks faced by clinical-stage biotechnology issuers.
Tap a question to reveal the answer.
Avg $2.50; min $1.86; max $3.63; ROI 85.1%; sentiment BULLISH.
The forecast shows rising averages and bullish sentiment from 2027 onward with positive ROI, though 2026 is neutral; for example 2027 avg $1.64 (ROI 21.8%), 2030 avg $2.50 (ROI 85.1%).
Yes—the 2034 max is $5.12 and 2035 max is $6.05.
Current price $1.35; market cap $336.55M.
Sentiment is BULLISH; RSI14 60; SMA50 $1.35; SMA200 $1.60; support $1.19; resistance $1.35; 30-day range low $1.13, high $1.61; annualized volatility 50%.
Lineage Cell Therapeutics, Inc. Community Discussion
0Share your Lineage Cell Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.